NAYA Biosciences Files S-1 Registration
Ticker: IVF · Form: S-1 · Filed: Dec 17, 2024 · CIK: 1417926
Sentiment: neutral
Topics: s-1, registration-statement, sec-filing
TL;DR
NAYA Biosciences just filed an S-1, get ready for a potential stock offering.
AI Summary
NAYA Biosciences, Inc. filed an S-1 registration statement on December 17, 2024, to register securities under the Securities Act of 1933. The company, formerly known as INVO Bioscience, Inc. and EMY'S SALSA AJI DISTRIBUTION COMPANY, INC., is incorporated in Nevada and headquartered in Sarasota, Florida. The filing indicates a potential offering of securities, though specific dollar amounts and dates for the offering are not detailed in this excerpt.
Why It Matters
This S-1 filing signals NAYA Biosciences' intent to offer securities to the public, which could lead to new funding for the company or a change in its stock structure.
Risk Assessment
Risk Level: medium — S-1 filings often precede significant corporate events like stock offerings, which carry inherent market risks.
Key Numbers
- 333-283872 — SEC File Number (Identifies this specific registration statement with the SEC.)
- 3841 — SIC Code (Indicates the company operates in the Surgical & Medical Instruments & Apparatus industry.)
Key Players & Entities
- NAYA Biosciences, Inc. (company) — Registrant
- INVO Bioscience, Inc. (company) — Former Company Name
- EMY'S SALSA AJI DISTRIBUTION COMPANY, INC. (company) — Former Company Name
- Steve Shum (person) — Chief Executive Officer
- Daniel Teper (person) — President
- December 17, 2024 (date) — Filing Date
FAQ
What is the purpose of this S-1 filing for NAYA Biosciences, Inc.?
The S-1 filing is a registration statement under the Securities Act of 1933, indicating the company's intent to offer securities to the public.
When was this S-1 filing submitted to the SEC?
The filing was submitted on December 17, 2024.
What were NAYA Biosciences, Inc.'s previous names?
NAYA Biosciences, Inc. was formerly known as INVO Bioscience, Inc. and EMY'S SALSA AJI DISTRIBUTION COMPANY, INC.
Where is NAYA Biosciences, Inc. headquartered?
The company's principal executive offices are located at 5582 Broadcast Court, Sarasota, Florida, 34240.
What industry does NAYA Biosciences, Inc. operate in?
The company's Standard Industrial Classification (SIC) code is 3841, which corresponds to Surgical & Medical Instruments & Apparatus.
Filing Stats: 4,380 words · 18 min read · ~15 pages · Grade level 15.9 · Accepted 2024-12-17 15:53:38
Key Financial Figures
- $10,000,000 — , 2024 NAYA Biosciences, Inc. Up to $10,000,000 of Units, each consisting of One Shar
- $0.0001 — of one share of common stock, par value $0.0001per share (the “Common Stock&rdquo
- $0 — includes a share of Common Stock, minus $0.01, and the exercise price of the Pre-F
- $0.01 — price of the Pre-Funded Warrant will be $0.01 per share. For each Unit including a Pr
- $0.82 — rted on Nasdaq on December 16, 2024 was $0.82 per share. We do not intend to apply to
Filing Documents
- forms-1.htm (S-1) — 1745KB
- ex10-68.htm (EX-10.68) — 127KB
- ex10-69.htm (EX-10.69) — 70KB
- ex10-70.htm (EX-10.70) — 92KB
- ex10-71.htm (EX-10.71) — 294KB
- ex10-72.htm (EX-10.72) — 369KB
- ex23-1.htm (EX-23.1) — 7KB
- ex107.htm (EX-FILING FEES) — 19KB
- forms1_001.jpg (GRAPHIC) — 26KB
- forms1_002.jpg (GRAPHIC) — 32KB
- forms1_003.jpg (GRAPHIC) — 176KB
- forms1_004.jpg (GRAPHIC) — 13KB
- forms1_005.jpg (GRAPHIC) — 163KB
- forms1_006.jpg (GRAPHIC) — 306KB
- forms1_007.jpg (GRAPHIC) — 200KB
- ex23-1_001.jpg (GRAPHIC) — 11KB
- ex10-69_001.jpg (GRAPHIC) — 121KB
- ex10-69_002.jpg (GRAPHIC) — 57KB
- ex10-69_003.jpg (GRAPHIC) — 24KB
- ex10-69_004.jpg (GRAPHIC) — 27KB
- ex10-69_005.jpg (GRAPHIC) — 31KB
- 0001493152-24-050393.txt ( ) — 4360KB
BUSINESS
BUSINESS DESCRIPTION 59 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 72
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION 94
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 102 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE 103
DESCRIPTION OF SECURITIES
DESCRIPTION OF SECURITIES 104 PLAN OF DISTRIBUTION 109 LEGAL MATTERS 116 EXPERTS 116 WHERE YOU CAN FIND MORE INFORMATION 116 INCORPORATION OF DOCUMENTS BY REFERENCE 117 PROSPECTUS SUMMARY This summary highlights selected information contained elsewhere in this prospectus or incorporated by reference into this prospectus. This summary does not contain all of the information that you should consider before investing in our Common Stock. You should carefully read this entire prospectus, and our other filings with the SEC, including the following sections, which are either included herein and/or incorporated by reference herein, “Risk Factors”, “Special Note Regarding Forward-Looking Statements”, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and the consolidated financial statements incorporated by reference herein, before making a decision about whether to invest in our securities . In this prospectus, unless context requires otherwise, references to “we,” “us,” “our,” “NAYA” or “the Company” refer to NAYA Biosciences, Inc. and its subsidiaries. THE COMPANY NAYA Biosciences is a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and fertility. The Company utilizes a hub and spoke model that harnesses the shared resources of a parent company and agility of lean strategic franchises, enabling efficient acquisition, development, and partnering of assets as well as optimized return on investment by combining the upside of innovative clinical-stage therapeutics with scalable, profitable commercial revenues. The hub-and-spoke structure uses a centralized portfolio management team (the parent company or “Hub”) that owns and controls a set of subsidiaries (“Spokes”). The subsidiaries remain focused on their as